Bio-Rad updates on Sartorius 2025 financial results

Bio-Rad Laboratories, Inc. filed an update on its investment in Sartorius AG, sharing Sartorius’ latest full-year 2025 financial figures that Sartorius disclosed on February 16, 2026.

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

8-K

Rhea-AI Filing Summary

Bio-Rad Laboratories, Inc. filed an update on its investment in Sartorius AG, sharing Sartorius’ latest full-year 2025 financial figures that Sartorius disclosed on February 16, 2026. The data come directly from Sartorius’ audited consolidated financial statements prepared under IFRS.

For the year ended December 31, 2025, Sartorius reported sales revenue of €3,538.1 million, gross profit of €1,636.7 million, earnings before interest and taxes (EBIT) of €542.6 million and net profit of €230.4 million. Cash flow from operating activities was €837.0 million, while cash flows from investing and financing activities were negative €513.7 million and €591.4 million, respectively. As of December 31, 2025, Sartorius reported current assets of €1,766.2 million, non-current assets of €7,951.1 million, current liabilities of €1,967.4 million, non-current liabilities of €3,882.6 million and equity of €3,867.2 million.

8-K Event Classification

Item 7.01 — Regulation FD Disclosure

1 item

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Bio-Rad (BIO) disclose about its investment in Sartorius AG?

Bio-Rad provided an informational update on its investment in Sartorius AG by summarizing Sartorius’ audited 2025 financial data. The figures, prepared under IFRS, include revenue, profits, cash flows, assets, liabilities, and equity as of December 31, 2025, as publicly disclosed by Sartorius.

What were Sartorius AG’s 2025 revenue and profitability figures reported by Bio-Rad (BIO)?

Sartorius AG reported 2025 sales revenue of €3,538.1 million, with gross profit of €1,636.7 million. Earnings before interest and taxes (EBIT) were €542.6 million, and net profit was €230.4 million, based on Sartorius’ consolidated financial statements referenced by Bio-Rad in the update.

How did Sartorius AG’s 2025 cash flows look in Bio-Rad’s (BIO) update?

For 2025, Sartorius AG generated cash flow from operating activities of €837.0 million. Cash flow from investing activities was negative €513.7 million, and cash flow from financing activities was negative €591.4 million, reflecting net cash outflows in investing and financing while operations remained strongly cash-generative.

What balance sheet data for Sartorius AG did Bio-Rad (BIO) highlight?

As of December 31, 2025, Sartorius AG reported current assets of €1,766.2 million and non-current assets of €7,951.1 million. Current liabilities were €1,967.4 million, non-current liabilities €3,882.6 million, and equity totaled €3,867.2 million, outlining Sartorius’ capital structure and leverage profile.

Which accounting standards were used for Sartorius AG’s figures in the Bio-Rad (BIO) disclosure?

The Sartorius AG financial data summarized by Bio-Rad come from consolidated statements prepared under International Financial Reporting Standards (IFRS), related IFRIC standards, and IASB requirements applicable in the European Union, as stated in Sartorius’ 2025 reporting referenced in the update.

Where can investors find more details on Sartorius AG referenced by Bio-Rad (BIO)?

Bio-Rad directs readers to Sartorius AG’s 2025 Annual Report for fuller details, available on Sartorius’ investor relations website at https://www.sartorius.com/en/company/investor-relations/sartorius-ag-investor-relations. Bio-Rad notes that Sartorius’ website and information are not incorporated by reference into the report.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 02/19/2026 - 04:15 PM EST

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report: February 19, 2026

(Date of earliest event reported)

BIO-RAD LABORATORIES, INC.

(Exact name of registrant as specified in its charter)

Commission File Number: 1-7928


Delaware						94-1381833
(State or other jurisdiction of incorporation)						(I.R.S. Employer Identification No.)

1000 Alfred Nobel Dr.

Hercules, California 94547

(Address of principal executive offices, including zip code)

(510)724-7000

(Registrant’s telephone number, including area code)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Class A Common Stock, Par Value $0.0001 per share

BIO

New York Stock Exchange

Class B Common Stock, Par Value $0.0001 per share

BIO.B

New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as deﬁned in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).


	Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.		☐

ITEM 7.01 Regulation FD Disclosure.

Bio-Rad Laboratories, Inc. (“Bio-Rad”) hereby provides the following update on information disclosed under the heading “Investment in Sartorius AG” in Part 1 Item 1 of Bio-Rad’s Form 10-K for the year ended December 31, 2025 that was filed on February 13, 2026 relating to Bio-Rad’s investment in Sartorius AG. The update relates to Sartorius AG’s financial results for the year ended December 31, 2025 that were disclosed by Sartorius AG on February 16, 2026.

Investment in Sartorius AG

The following summarizes certain financial data of Sartorius as of and for the year ended December 31, 2025, (in millions).


			December 31, 2025 (1)
Current assets			€ 1,766.2
Non-current assets			7,951.1
Current liabilities			1,967.4
Non-current liabilities			3,882.6
Equity			3,867.2

			Year Ended December 31, 2025 (1)
Sales revenue			€ 3,538.1
Gross profit on sales			1,636.7
Earnings before interest and taxes (EBIT)			542.6
Net profit			230.4

Cash flow from operating activities			837.0
Cash flow from investing activities			(513.7)
Cash flow from financing activities			(591.4)

1.As disclosed in Sartorius AG's consolidated financial statements for the year ended December 31, 2025, prepared in accordance with the International Financial Reporting Standards (IFRS), the International Financial Reporting Interpretations Committee (IFRIC) Standards, and the International Accounting Standards Board (IASB) as required to be applied by the European Union, and based upon information publicly disclosed by Sartorius. Bio-Rad does not assume, and by way of referencing the financial data of Sartorius above shall not be deemed to assume, any responsibility or liability for any errors or omissions in the information publicly disclosed by Sartorius.

Refer to Sartorius’ 2025 Annual Report for further details, which can be found at https://www.sartorius.com/en/company/investor-relations/sartorius-ag-investor-relations. The Sartorius website and any information disclosed thereon are not incorporated by reference into this report.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BIO-RAD LABORATORIES, INC.

Date:

February 19, 2026

By:

/s/ Courtney C. Enloe

Courtney C. Enloe

Executive Vice President, General Counsel and Secretary

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

4 documents